Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:19PM ET
13.65
Dollar change
+0.48
Percentage change
3.64
%
IndexRUT P/E- EPS (ttm)-3.15 Insider Own20.40% Shs Outstand35.84M Perf Week19.74%
Market Cap489.22M Forward P/E- EPS next Y-5.99 Insider Trans0.07% Shs Float28.53M Perf Month26.62%
Income-112.64M PEG- EPS next Q-0.98 Inst Own81.29% Short Float7.06% Perf Quarter26.86%
Sales12.60M P/S38.83 EPS this Y-46.75% Inst Trans-2.42% Short Ratio7.63 Perf Half Y18.59%
Book/sh16.05 P/B0.85 EPS next Y-29.55% ROA-15.84% Short Interest2.01M Perf Year-2.08%
Cash/sh14.84 P/C0.92 EPS next 5Y- ROE-18.19% 52W Range8.20 - 18.24 Perf YTD24.66%
Dividend Est.- P/FCF- EPS past 5Y-40.62% ROI-19.42% 52W High-25.16% Beta1.18
Dividend TTM- Quick Ratio13.76 Sales past 5Y-24.09% Gross Margin93.02% 52W Low66.46% ATR (14)0.63
Dividend Ex-Date- Current Ratio13.76 EPS Y/Y TTM-215.69% Oper. Margin-1198.71% RSI (14)70.13 Volatility4.78% 5.13%
Employees157 Debt/Eq0.01 Sales Y/Y TTM-95.29% Profit Margin-894.35% Recom1.00 Target Price34.40
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-257.87% Payout0.00% Rel Volume1.09 Prev Close13.17
Sales Surprise-100.00% EPS Surprise17.73% Sales Q/Q-100.00% EarningsMar 06 BMO Avg Volume263.90K Price13.65
SMA2019.77% SMA5026.45% SMA20020.05% Trades Volume217,275 Change3.64%
Date Action Analyst Rating Change Price Target Change
May-05-21Initiated H.C. Wainwright Buy $37
Oct-08-20Initiated Robert W. Baird Outperform $45
Aug-18-20Initiated Wedbush Outperform $45
Aug-18-20Initiated SVB Leerink Outperform $45
Aug-18-20Initiated Piper Sandler Overweight $50
Aug-18-20Initiated JP Morgan Overweight $40
Mar-06-24 02:51PM
07:01AM
07:00AM
Mar-05-24 04:30PM
Mar-01-24 07:00AM
06:11AM Loading…
Feb-26-24 06:11AM
Jan-08-24 07:00AM
Jan-03-24 07:00AM
Dec-13-23 09:55AM
Nov-27-23 09:55AM
Nov-21-23 07:00AM
Nov-13-23 09:55AM
Nov-10-23 09:55AM
Nov-07-23 07:00AM
Oct-31-23 03:01AM
01:46PM Loading…
Oct-16-23 01:46PM
04:38AM
Oct-11-23 05:55PM
Sep-06-23 07:00AM
Aug-26-23 11:02AM
Aug-24-23 11:30AM
Aug-23-23 04:10PM
02:00PM
09:24AM
Aug-08-23 07:00AM
Jun-21-23 08:00PM
May-13-23 08:03AM
May-11-23 06:11AM
May-10-23 08:35AM
07:01AM
08:51AM Loading…
May-05-23 08:51AM
Apr-26-23 08:00PM
Mar-23-23 01:56PM
Mar-21-23 06:07AM
Mar-17-23 06:18AM
Mar-15-23 08:35AM
07:00AM
Feb-28-23 07:00AM
Feb-07-23 01:51PM
07:00AM
Feb-02-23 02:19PM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-07-22 08:07AM
Nov-22-22 07:00AM
Nov-10-22 07:55PM
04:01PM
Nov-04-22 05:46PM
Nov-02-22 10:00AM
Oct-18-22 08:36AM
Aug-12-22 06:16AM
Aug-10-22 05:25PM
04:01PM
Aug-02-22 07:00AM
Jun-30-22 08:41AM
May-16-22 06:27AM
May-12-22 05:45PM
04:01PM
May-11-22 04:09PM
07:03AM
Apr-08-22 01:00PM
Mar-26-22 02:51PM
Mar-23-22 05:55PM
04:01PM
Mar-01-22 07:00AM
Feb-24-22 07:55AM
Feb-10-22 07:00AM
Feb-01-22 09:38AM
Jan-19-22 09:38AM
Jan-10-22 07:00AM
Jan-03-22 04:46PM
04:01PM
Dec-31-21 05:44PM
Dec-29-21 12:19PM
Dec-23-21 12:38PM
09:15AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-10-21 09:38PM
Dec-09-21 04:01PM
Nov-22-21 10:38AM
Nov-16-21 12:20PM
11:07AM
Nov-10-21 05:45PM
04:01PM
Nov-04-21 11:24AM
Nov-03-21 07:00AM
Oct-18-21 10:26AM
Sep-02-21 10:11AM
Sep-01-21 07:00AM
Aug-12-21 07:00AM
Aug-05-21 07:00AM
Aug-03-21 07:00AM
Jul-08-21 10:03AM
Jun-17-21 06:40AM
Jun-16-21 02:34PM
Jun-15-21 08:11AM
Jun-14-21 04:55PM
08:42AM
07:53AM
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gall MatthewChief Financial OfficerOct 12 '23Buy8.375,00041,85019,429Oct 12 05:09 PM
Boxer Capital, LLCAug 23 '23Sale16.26350,0005,692,6731,804,058Aug 25 09:28 PM